TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07901114: A Randomized, Open-Label, Fasting, 2-Period, 2-Sequence Crossover Study to Evaluate the Bioequivalence and Safety of AJU-C719 and C719R in Healthy Adult Volunteers

Sponsor: AJU Pharm Co., Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07901114 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07901114 Rescue Dossier →